Journal: Journal of Biomedical Materials Research. Part B, Applied Biomaterials

Article Title: Dehydrated human amniotic membrane regulates tenocyte expression and angiogenesis in vitro : Implications for a therapeutic treatment of tendinopathy

doi: 10.1002/jbm.b.34951

Figure Lengend Snippet: Pro‐angiogenic effects of μdHACM. On Day 2, treatments, including assay medium + 4 ng/ml VEGF (positive control), assay medium + 4 ng/ml VEGF + 100 μM suramin (negative control), assay medium alone (vehicle control), or μdHACM extracts at 5, 2.5, and 0.2 mg/ml concentrations in assay medium were added to the co‐cultures using each tenocyte donor. Time course image analysis was performed measuring (a–c) network branch points (per mm 2 ), (d–f) network length (mm/mm 2 ), and (g–i) average network length (mm) in response to μdHACM treatment. Error bars represent the SD from the mean values. n = 3 μdHACM donors. VEGF, vascular endothelial growth factor; μdHACM, micronized dehydrated human amnion/chorion membrane

Article Snippet: The ability of antagonists to bind or antagonize soluble VEGF was evaluated by incubating recombinant VEGF (4 ng/ml) with the treatment groups for 5 min at 37°C, followed by immediate quantification of the unbound VEGF by ELISA (DVE00; R&D Systems, Minneapolis, MN).

Techniques: Positive Control Assay, Negative Control, Control, Membrane

Journal: Journal of Biomedical Materials Research. Part B, Applied Biomaterials

Article Title: Dehydrated human amniotic membrane regulates tenocyte expression and angiogenesis in vitro : Implications for a therapeutic treatment of tendinopathy

doi: 10.1002/jbm.b.34951

Figure Lengend Snippet: Anti‐angiogenic response of μdHACM in the presence of VEGF. On Day 2 of co‐culture, μdHACM treatments were added in the presence of 4 ng/ml VEGF. Time course image analysis was performed in co‐culture with the three different tenocyte donors measuring (a–c) network branch points (per mm 2 ), (d–f) network length (mm/mm 2 ), and (g–i) average network length (mm) in response to μdHACM treatment. Error bars represent the SD from the mean values. n = 3 μdHACM donors. VEGF, vascular endothelial growth factor; μdHACM, micronized dehydrated human amnion/chorion membrane

Article Snippet: The ability of antagonists to bind or antagonize soluble VEGF was evaluated by incubating recombinant VEGF (4 ng/ml) with the treatment groups for 5 min at 37°C, followed by immediate quantification of the unbound VEGF by ELISA (DVE00; R&D Systems, Minneapolis, MN).

Techniques: Co-Culture Assay, Membrane

Journal: Journal of Biomedical Materials Research. Part B, Applied Biomaterials

Article Title: Dehydrated human amniotic membrane regulates tenocyte expression and angiogenesis in vitro : Implications for a therapeutic treatment of tendinopathy

doi: 10.1002/jbm.b.34951

Figure Lengend Snippet: Vascular disruption potential of μdHACM. HUVECs formed networks in the presence of VEGF over 3 days followed by treatment with μdHACM + VEGF for 3 days. Time course image analysis was performed measuring (a–c) network branch points (per mm 2 ), (d–f) network length (mm/mm 2 ), and (g–i) average network length (mm) in response to μdHACM treatment. Error bars represent the SD from the mean values. n = 3 μdHACM donors. HUVEC, human umbilical vein endothelial cells; VEGF, vascular endothelial growth factor; μdHACM, micronized dehydrated human amnion/chorion membrane

Article Snippet: The ability of antagonists to bind or antagonize soluble VEGF was evaluated by incubating recombinant VEGF (4 ng/ml) with the treatment groups for 5 min at 37°C, followed by immediate quantification of the unbound VEGF by ELISA (DVE00; R&D Systems, Minneapolis, MN).

Techniques: Disruption, Membrane

Journal: Journal of Biomedical Materials Research. Part B, Applied Biomaterials

Article Title: Dehydrated human amniotic membrane regulates tenocyte expression and angiogenesis in vitro : Implications for a therapeutic treatment of tendinopathy

doi: 10.1002/jbm.b.34951

Figure Lengend Snippet: VEGF bioavailability. Soluble factors in μdHACM extract bind VEGF. Error bars represent the SD from the mean values. * p < .05 versus positive control, n = 6 μdHACM donors. VEGF, vascular endothelial growth factor; μdHACM, micronized dehydrated human amnion/chorion membrane

Article Snippet: The ability of antagonists to bind or antagonize soluble VEGF was evaluated by incubating recombinant VEGF (4 ng/ml) with the treatment groups for 5 min at 37°C, followed by immediate quantification of the unbound VEGF by ELISA (DVE00; R&D Systems, Minneapolis, MN).

Techniques: Positive Control, Membrane

Journal: Cancer Chemotherapy and Pharmacology

Article Title: A pharmacokinetic binding model for bevacizumab and VEGF 165 in colorectal cancer patients

doi: 10.1007/s00280-015-2701-3

Figure Lengend Snippet: Patient and study characteristics

Article Snippet: The concentration of free VEGF 165 (unbound to bevacizumab) in serum was measured by a commercially available ELISA kit for VEGF 165 (Quantikine ® human VEGF, R&D Systems ® Europe).

Techniques:

Journal: Cancer Chemotherapy and Pharmacology

Article Title: A pharmacokinetic binding model for bevacizumab and VEGF 165 in colorectal cancer patients

doi: 10.1007/s00280-015-2701-3

Figure Lengend Snippet: In vitro VEGF 165 concentrations after addition of bevacizumab

Article Snippet: The concentration of free VEGF 165 (unbound to bevacizumab) in serum was measured by a commercially available ELISA kit for VEGF 165 (Quantikine ® human VEGF, R&D Systems ® Europe).

Techniques: In Vitro

Journal: Cancer Chemotherapy and Pharmacology

Article Title: A pharmacokinetic binding model for bevacizumab and VEGF 165 in colorectal cancer patients

doi: 10.1007/s00280-015-2701-3

Figure Lengend Snippet: Population parameter estimates from the PK model (bevacizumab analyzed alone) and TMDD model (bevacizumab and VEGF 165 analyzed simultaneously)

Article Snippet: The concentration of free VEGF 165 (unbound to bevacizumab) in serum was measured by a commercially available ELISA kit for VEGF 165 (Quantikine ® human VEGF, R&D Systems ® Europe).

Techniques:

Journal: Cancer Chemotherapy and Pharmacology

Article Title: A pharmacokinetic binding model for bevacizumab and VEGF 165 in colorectal cancer patients

doi: 10.1007/s00280-015-2701-3

Figure Lengend Snippet: Structure of the binding model for bevacizumab–VEGF 165 interaction. The approximation CL RC = CL was used for purposes of model fitting

Article Snippet: The concentration of free VEGF 165 (unbound to bevacizumab) in serum was measured by a commercially available ELISA kit for VEGF 165 (Quantikine ® human VEGF, R&D Systems ® Europe).

Techniques: Binding Assay

Journal: Cancer Chemotherapy and Pharmacology

Article Title: A pharmacokinetic binding model for bevacizumab and VEGF 165 in colorectal cancer patients

doi: 10.1007/s00280-015-2701-3

Figure Lengend Snippet: Prediction-corrected visual predictive checks of the binding model based on 1000 simulations (panel a total bevacizumab, panel b free VEGF 165 ). Median ( solid line ), 10th and 90th percentiles ( dashed lines ) of the observed data ( circles ) are compared to the 95 % confidence intervals ( shaded areas ) for the median, 10th and 90th percentiles of the simulated data

Article Snippet: The concentration of free VEGF 165 (unbound to bevacizumab) in serum was measured by a commercially available ELISA kit for VEGF 165 (Quantikine ® human VEGF, R&D Systems ® Europe).

Techniques: Binding Assay

Journal: Cancer Chemotherapy and Pharmacology

Article Title: A pharmacokinetic binding model for bevacizumab and VEGF 165 in colorectal cancer patients

doi: 10.1007/s00280-015-2701-3

Figure Lengend Snippet: Model-predicted concentrations of total bevacizumab, total and free VEGF 165 for a typical patient of 70 kg. Panels a , b show the total bevacizumab and free VEGF 165 concentration profiles at doses of 5 and 7.5 mg/kg, respectively. Panel c depicts the total VEGF 165 profiles over time for the two dosing regimens

Article Snippet: The concentration of free VEGF 165 (unbound to bevacizumab) in serum was measured by a commercially available ELISA kit for VEGF 165 (Quantikine ® human VEGF, R&D Systems ® Europe).

Techniques: Concentration Assay